Blood-based cfDNA test trial aims to reduce CRC screening disparities

▪ SCREENING

A randomized trial is underway to test whether offering an FDA-approved cell-free tumor DNA blood test as an expanded screening option improves participation rates, especially among lower-income and racial/ethnic minoritized groups who face disproportionate CRC outcome inequities. (BMJ Open)